# FDA 483 - Peyman Saadat MD, Inc. - February 20, 2024

Source: https://www.keypedia.com/records/483/peyman-saadat-md-inc/edbaeade-82ab-48bf-99c3-0a9a392832fa

> FDA 483 for Peyman Saadat MD, Inc. on February 20, 2024. Product: other. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Peyman Saadat MD, Inc.
- Inspection Date: 2024-02-20
- Product Type: other
- Office Name: Division of Pharmaceutical Quality Operations IV
- Summary: An FDA inspection of Peyman Saadat MD, Inc., a Reproductive Fertility Center in West Hollywood, CA, identified two significant observations. The firm made Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) available for distribution before completing donor eligibility determinations. Additionally, the firm's HCT/P records lacked the required statement confirming communicable disease testing was performed by a CLIA-certified laboratory or one meeting equivalent CMS requirements.

## Related Officers

- [Dylan R. Jock](https://www.keypedia.com/people/dylan-r-jock/a083cb5e-95d7-491d-9c6d-8c36c5963ddf)

Company: https://www.keypedia.com/companies/peyman-saadat-md-inc/2128187d-8aeb-4e88-ad5f-ae65b674bae7

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iv/a2d2ff91-dc0f-433e-b91f-ca90ff8998b6